923237-42-7

Usage

Uses

Used in Pharmaceutical Industry:
1-(3,4-difluorobenzoyl)piperazine is used as a pharmaceutical compound for its potential therapeutic applications. Its unique chemical structure allows it to interact with specific biological targets, making it a candidate for the development of new drugs to treat various medical conditions.
Used in Drug Development Research:
1-(3,4-difluorobenzoyl)piperazine is used as a research compound for exploring its pharmacological properties and potential applications in drug development. Its study can lead to a better understanding of its mechanisms of action and help in the design of more effective drugs targeting specific diseases.
Used in Chemical Synthesis:
1-(3,4-difluorobenzoyl)piperazine can be used as a building block or intermediate in the synthesis of more complex molecules with potential applications in various industries, including pharmaceuticals, agrochemicals, and materials science. Its unique structure and functional groups make it a valuable component in the development of novel compounds with specific properties and applications.

Upstream product

• 110-85-0 piperazine 
• 455-86-7 3,4-Difluorobenzoic acid 
• 142-64-3 piperazine dihydrochloride 

Relevant academic research and scientific papers

A N, 6 diphenyl pyrimidine -4 - amine Bcr - Abl inhibitor and its preparation method and application (by machine translation)

The invention discloses a N, 6 diphenyl pyrimidine - 4 - amine Bcr - Abl inhibitor and its preparation method and application, the structural formula of the inhibitor for the wherein R is a single substituent or double-substituent, substituent is alkyl or halogen; R1 As a single substituent or double-substituent, substituent is alkyl or halogen. The series of inhibitors in vitro ABL1 kinase restraining effects, and can inhibit the proliferation of tumor cells, can be used for anti-tumor pharmaceutical preparation, in particular CML (chronic granulocytic leukemia) drug. The invention provides N, 6 diphenyl pyrimidine - 4 - amine Bcr - Abl inhibitor preparation method, raw materials are apt, mild reaction conditions, the reaction process is simple in operation, reagent used and cheap. (by machine translation)

Expanding the structural diversity of Bcr-Abl inhibitors: Hybrid molecules based on GNF-2 and Imatinib

In order to expand the structural diversity of Bcr-Abl inhibitors, twenty hybrids (series E and P) have been synthesized and characterized based on Imatinib and GNF-2. Their biological activities were evaluated in vitro against human leukemia cells. Most compounds exhibited potent antiproliferative activity against K562 cells, especially for compounds E4, E5 and E7. Furthermore, these new hybrids were also screened for Abl kinase inhibitory activity, and some of them inhibited Abl kinase with low micromolar IC50 values. In particular, compound P3 displayed the most potent activity with IC50 value of 0.017 μM comparable with that of Imatinib. Molecular docking studies indicated that these novel hybrids fitted well with the active site of Bcr-Abl. These results suggested the great potential of these compounds as novel Bcr-Abl inhibitors.

Discovery of novel Bcr-Abl inhibitors with diacylated piperazine as the flexible linker

Forty-two compounds (series 8, 9 and 10) incorporated with diacylated piperazine have been synthesized and evaluated as novel Bcr-Abl inhibitors based on 'six-atom linker'. Five of them, 8d, 8h, 8l, 10m and 10p, displayed potent Bcr-Abl inhibitory activity comparable with Imatinib. Moreover, compounds 8e, 10q, 10s, and 10u were potent Bcr-Abl inhibitors with IC50 values at the sub-micromolecular level. Most compounds exhibited moderate to high antiproliferative activity against K562 cells. In particular, compound 9e was the most promising Bcr-Abl inhibitor. Docking studies revealed that the binding modes of these compounds were similar with Imatinib. These compounds could be considered as promising lead compounds for further optimization.